Fig. 4.

LS mean change from baseline in DLQI. Patients aged < 60 years treated with dupilumab 300 mg qw or q2w achieved a greater LS mean change from baseline in DLQI from week 1 through week 16 vs placebo (P < 0.0001). Patients aged ≥ 60 years treated with dupilumab 300 mg qw showed a greater LS mean change from baseline in DLQI at week 1 vs placebo (P < 0.05), with dupilumab q2w from week 2 vs placebo (P < 0.001), and with dupilumab qw or q2w from week 4 through week 16 (P < 0.0001). DLQI Dermatology Life Quality Index, LS least squares, q2w every 2 weeks, qw every week. *P < 0.05; **P < 0.001; ***P < 0.0001